|
1
|
Schmitt SM, Frezza M and Dou QP: New
applications of old metal-binding drugs in the treatment of human
cancer. Front Biosci (Schol Ed). 4:375–391. 2012. View Article : Google Scholar
|
|
2
|
Santini C, Pellei M, Gandin V, Porchia M,
Tisato F and Marzano C: Advances in copper complexes as anticancer
agents. Chem Rev. 114:815–862. 2014. View Article : Google Scholar
|
|
3
|
Krajčiová D, Melník M, Havránek E,
Forgácsová A and Mikuš P: Copper compounds in nuclear medicine and
oncology. J Coord Chem. 67:1493–1519. 2014. View Article : Google Scholar
|
|
4
|
Buac D, Schmitt S, Ventro G, Kona FR and
Dou QP: Dithiocarbamate-based coordination compounds as potent
proteasome inhibitors in human cancer cells. Mini Rev Med Chem.
12:1193–1201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen D, Cui QC, Yang H and Dou QP:
Disulfiram, a clinically used anti-alcoholism drug and
copper-binding agent, induces apoptotic cell death in breast cancer
cultures and xenografts via inhibition of the proteasome activity.
Cancer Res. 66:10425–10433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhai S, Yang L, Cui QC, Sun Y, Dou QP and
Yan B: Tumor cellular proteasome inhibition and growth suppression
by 8-hydroxyquinoline and clioquinol requires their capabilities to
bind copper and transport copper into cells. J Biol Inorg Chem.
15:259–269. 2010. View Article : Google Scholar :
|
|
7
|
Chen D, Cui QC, Yang H, Barrea RA, Sarkar
FH, Sheng S, Yan B, Reddy GP and Dou QP: Clioquinol, a therapeutic
agent for Alzheimer's disease, has proteasome-inhibitory, androgen
receptor-suppressing, apoptosis-inducing, and antitumor activities
in human prostate cancer cells and xenografts. Cancer Res.
67:1636–1644. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adsule S, Barve V, Chen D, Ahmed F, Dou
QP, Padhye S and Sarkar FH: Novel Schiff base copper complexes of
quinoline-2 carboxaldehyde as proteasome inhibitors in human
prostate cancer cells. J Med Chem. 49:7242–7246. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Creaven BS, Czeglédi E, Devereux M, Enyedy
ÉA, Foltyn-Arfa Kia A, Karcz D, Kellett A, McClean S, Nagy NV,
Noble A, et al: Biological activity and coordination modes of
copper(II) complexes of Schiff base-derived coumarin ligands.
Dalton Trans. 39:10854–10865. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Z, Bi C, Fan Y, Zhang N, Deshmukh R,
Yan X, Lv X, Zhang P, Zhang X and Dou QP: L-Ornithine Schiff
base-copper and -cadmium complexes as new proteasome inhibitors and
apoptosis inducers in human cancer cells. J Biol Inorg Chem.
20:109–121. 2015. View Article : Google Scholar
|
|
11
|
Nalepa G, Rolfe M and Harper JW: Drug
discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov.
5:596–613. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Peters JM, Cejka Z, Harris JR,
Kleinschmidt JA and Baumeister W: Structural features of the 26 S
proteasome complex. J Mol Biol. 234:932–937. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Groll M, Ditzel L, Löwe J, Stock D,
Bochtler M, Bartunik HD and Huber R: Structure of 20S proteasome
from yeast at 2.4 A resolution. Nature. 386:463–471. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Groll M, Heinemeyer W, Jäger S, Ullrich T,
Bochtler M, Wolf DH and Huber R: The catalytic sites of 20S
proteasomes and their role in subunit maturation: A mutational and
crystallographic study. Proc Natl Acad Sci USA. 96:10976–10983.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adams J: The proteasome: A suitable
antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Frezza M, Schmitt S and Dou QP: Targeting
the ubiquitin-proteasome pathway: An emerging concept in cancer
therapy. Curr Top Med Chem. 11:2888–2905. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lopes UG, Erhardt P, Yao R and Cooper GM:
p53-dependent induction of apoptosis by proteasome inhibitors. J
Biol Chem. 272:12893–12896. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
An B, Goldfarb RH, Siman R and Dou QP:
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective
function and selectively accumulate the cyclin-dependent kinase
inhibitor p27 and induce apoptosis in transformed, but not normal,
human fibroblasts. Cell Death Differ. 5:1062–1075. 1998. View Article : Google Scholar
|
|
19
|
Rajkumar SV, Richardson PG, Hideshima T
and Anderson KC: Proteasome inhibition as a novel therapeutic
target in human cancer. J Clin Oncol. 23:630–639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Verani CN: Metal complexes as inhibitors
of the 26S proteasome in tumor cells. J Inorg Biochem. 106:59–67.
2012. View Article : Google Scholar
|
|
21
|
Unno M, Mizushima T, Morimoto Y, Tomisugi
Y, Tanaka K, Yasuoka N and Tsukihara T: The structure of the
mammalian 20S proteasome at 2.75 A resolution. Structure.
10:609–618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Z, Bi C, Schmitt SM, Fan Y, Dong L,
Zuo J and Dou QP: 1,10-Phenanthroline promotes copper complexes
into tumor cells and induces apoptosis by inhibiting the proteasome
activity. J Biol Inorg Chem. 17:1257–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Z, Bi C, Buac D, Fan Y, Zhang X, Zuo
J, Zhang P, Zhang N, Dong L and Dou QP: Organic cadmium complexes
as proteasome inhibitors and apoptosis inducers in human breast
cancer cells. J Inorg Biochem. 123:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Z, Bi C, Fan Y, Wang H and Bao Y:
Cefepime, a fourth-generation cephalosporin, in complex with
manganese, inhibits proteasome activity and induces the apoptosis
of human breast cancer cells. Int J Mol Med. 36:1143–1150.
2015.PubMed/NCBI
|
|
25
|
Zhang N, Fan YH, Zhang Z, Zuo J, Zhang PF,
Wang Q, Liu SB and Bi CF: Syntheses, crystal structures and
anticancer activities of three novel transition metal complexes
with Schiff base derived from 2-acetylpyridine and l-tryptophan.
Inorg Chem Commun. 22:68–72. 2012. View Article : Google Scholar
|
|
26
|
Daniel KG, Chen D, Orlu S, Cui QC, Miller
FR and Dou QP: Clioquinol and pyrrolidine dithiocarbamate complex
with copper to form proteasome inhibitors and apoptosis inducers in
human breast cancer cells. Breast Cancer Res. 7:R897–R908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen D, Peng F, Cui QC, Daniel KG, Orlu S,
Liu J and Dou QP: Inhibition of prostate cancer cellular proteasome
activity by a pyrrolidine dithiocarbamate-copper complex is
associated with suppression of proliferation and induction of
apoptosis. Front Biosci. 10:2932–2939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jones G, Willett P and Glen RC: Molecular
recognition of receptor sites using a genetic algorithm with a
description of desolvation. J Mol Biol. 245:43–53. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kazuo N, Huang DR and Wang QR: Infrared
and Raman spectra of inorganic and coordination compounds. Chemical
Industry Press; Beijing: 1988
|
|
30
|
Gong QJ, Jin WJ, Dong C and Liu CS:
Synthesis of new fluorescence reagent: 4-Aminoantipyrine aromatic
Schiff bases. Appl Chem. 17:227–229. 2000.
|
|
31
|
Li B and Dou QP: Bax degradation by the
ubiquitin/proteasome-dependent pathway: Involvement in tumor
survival and progression. Proc Natl Acad Sci USA. 97:3850–3855.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Orlowski RZ and Kuhn DJ: Proteasome
inhibitors in cancer therapy: Lessons from the first decade. Clin
Cancer Res. 14:1649–1657. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kane RC, Bross PF, Farrell AT and Pazdur
R: Velcade: U.S. FDA approval for the treatment of multiple myeloma
progressing on prior therapy. Oncologist. 8:508–513. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dou QP and Zonder JA: Overview and
perspective of proteasome inhibitor-based anti-cancer therapies:
Bortezomib and second generation proteasome inhibitors versus
future generation inhibitors of ubiquitin-proteasome system. Curr
Cancer Drug Targets. 14:517–536. 2014. View Article : Google Scholar
|
|
35
|
Lee EC, Fitzgerald M, Bannerman B, Donelan
J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, et
al: Antitumor activity of the investigational proteasome inhibitor
MLN9708 in mouse models of B-cell and plasma cell malignancies.
Clin Cancer Res. 17:7313–7323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shirley M: Ixazomib: First Global
Approval. Drugs. 76:405–411. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Offidani M, Corvatta L, Gentili S, Maracci
L and Leoni P: Oral ixazomib maintenance therapy in multiple
myeloma. Expert Rev Anticancer Ther. 16:21–32. 2016. View Article : Google Scholar
|
|
38
|
Milacic V, Chen D, Giovagnini L, Diez A,
Fregona D and Dou QP: Pyrrolidine dithiocarbamate-zinc(II) and
-copper(II) complexes induce apoptosis in tumor cells by inhibiting
the proteasomal activity. Toxicol Appl Pharmacol. 231:24–33. 2008.
View Article : Google Scholar : PubMed/NCBI
|
